Mr. Andre Larente reports

DIAGNOS WELCOMES FORMER WHITE HOUSE ECONOMIC ADVISER DR. TOMAS J. PHILIPSON TO ITS ADVISORY BOARD FOR THE US MARKET

Dr. Tomas J. Philipson has joined Diagnos Inc.'s advisory board.

Dr. Philipson is considered an expert in U.S. economic policy, particularly health care policy and appears often on major media outlets, including Forbes, The Economist, The Wall Street Journal, The New York Times, CNN, BBC, CBS, ABC, CNBC, Fox News, Fox Business, Newsmax, Yahoo Finance, American Voice, Bloomberg and CSPAN.

He currently serves as managing partner of the venture capital firm Meda Ventures, serves on several corporate boards and has co-founded several companies, including Precision Health Economics LLC, with an exit in 2015 (currently owned by Blackstone).

His government service includes a full-time position as vice-chairman and acting chairman of the White House Council of Economic Advisers from 2017 to 2020. He previously served as a senior economic adviser to the head of the U.S. Food and Drug Administration (FDA) and a senior economic adviser to the head of the Centers for Medicare and Medicaid Services (CMS). Dr. Philipson was appointed to the Key Indicator Commission by the Speaker of the House of Representatives in 2012. He was a scientific adviser to the House of Representatives initiative 21st Century Cures in 2015 and the Biden Cancer Initiative in 2017. He served as a health care adviser to Senator John McCain's 2008 presidential campaign.

He received numerous worldwide research awards while he was a chaired professor at the University of Chicago. He is a two-time winner of the Arrow Award of the International Health Economics Association, the highest honour in health economics. Other awards include the Garfield Award for Economic Research, the Premio Haralambos Simeonidis from the Brazilian Economic Association and the Milken Institute's Distinguished Economic Research Award.

He received a BA in mathematics from Uppsala University in Sweden, an MA in mathematics from Claremont Graduate School, and an MA and PhD in economics from the Wharton School and the University of Pennsylvania.

"We are honoured to welcome Dr. Philipson to our adviser board," said Andre Larente, president and chief executive officer of Diagnos. "His extensive experience at the highest levels of government and business savvy brings a vital perspective to today's policy challenges, from health care innovation to long-term economic competitiveness."

Mr. Larente added: "Diagnos has built an AI [artificial intelligence] platform to analyze retina images; these images are taken by thousands of optometrists worldwide. According to the VisionWatch data, the U.S. saw approximately 111 million routine eye exams and 60 million medical eye exams in 2020. Diagnos, along with its partners, can address this growing market." Diagnos recently opened its U.S. office in southern Florida to support its prospects and clients.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.